Plus Therapeutics (PSTV) News Today $1.30 +0.01 (+0.78%) (As of 11/13/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period A Peek at Plus Therapeutics's Future EarningsNovember 13 at 6:55 PM | benzinga.comPlus Therapeutics (PSTV) Scheduled to Post Quarterly Earnings on ThursdayNovember 13 at 2:27 AM | americanbankingnews.comPlus Therapeutics, SpectronRx announce manufacturing partnershipNovember 6, 2024 | markets.businessinsider.comPlus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing PartnershipNovember 6, 2024 | globenewswire.comPlus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024November 5, 2024 | globenewswire.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, TexasOctober 29, 2024 | globenewswire.comPlus Therapeutics reports progress in brain cancer trialOctober 3, 2024 | uk.investing.comPlus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual MeetingOctober 1, 2024 | globenewswire.comDow Tumbles Over 200 Points; Carnival Posts Upbeat EarningsSeptember 30, 2024 | benzinga.comPlus Therapeutics (NASDAQ:PSTV) Stock, Short Interest ReportSeptember 29, 2024 | benzinga.comPlus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual MeetingSeptember 18, 2024 | globenewswire.comPlus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comBuy Rating Affirmed for Plus Therapeutics Amid Strong Clinical Results and Positive Financial OutlookAugust 20, 2024 | markets.businessinsider.comPlus Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsAugust 17, 2024 | finance.yahoo.comBuy Rating Affirmed for Plus Therapeutics Amidst Promising Clinical Trial ResultsAugust 15, 2024 | markets.businessinsider.comQ2 2024 Plus Therapeutics Inc Earnings CallAugust 15, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comPlus Therapeutics reports progress in CNS cancer trialAugust 14, 2024 | uk.investing.comPlus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 14, 2024 | globenewswire.comPlus Therapeutics earnings: here's what Wall Street expectsAugust 14, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases ConferenceAugust 14, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases ConferenceAugust 13, 2024 | globenewswire.comPlus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases ConferenceAugust 12, 2024 | globenewswire.comPlus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024August 8, 2024 | globenewswire.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 25, 2024 | markets.businessinsider.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 25, 2024 | globenewswire.comPlus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of CancerJuly 2, 2024 | globenewswire.comPlus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRITJune 7, 2024 | globenewswire.comPlus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement GrantsMay 18, 2024 | finanznachrichten.dePlus Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comPlus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 16, 2024 | finance.yahoo.comPlus: Q1 Earnings SnapshotMay 15, 2024 | sfgate.comPlus Therapeutics Inc. Q1 Loss Decreases, Beats EstimatesMay 15, 2024 | markets.businessinsider.comPlus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 15, 2024 | globenewswire.comPlus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024May 13, 2024 | globenewswire.comPlus Therapeutics CEO buys $25,000 in company stockMay 12, 2024 | uk.investing.comAndrew John Hugh Macintyr Sims Acquires 4,902 Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) StockMay 11, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)May 10, 2024 | markets.businessinsider.comPlus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE TrialMay 9, 2024 | globenewswire.comPlus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialMay 8, 2024 | globenewswire.comMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseApril 22, 2024 | finance.yahoo.comPlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseApril 22, 2024 | globenewswire.comPlus Therapeutics, Inc. (PSTV)April 19, 2024 | finance.yahoo.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamApril 9, 2024 | finance.yahoo.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.April 9, 2024 | globenewswire.comPlus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceMarch 27, 2024 | finance.yahoo.comPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticMarch 25, 2024 | finance.yahoo.comBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsMarch 23, 2024 | markets.businessinsider.comPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesMarch 11, 2024 | finance.yahoo.com Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov PSTV Media Mentions By Week PSTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼0.470.55▲Average Medical News Sentiment PSTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼21▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Interpace Biosciences News Today Nexalin Technology News Today DarioHealth News Today Spectral AI News Today Precision Optics News Today Femasys News Today BioSig Technologies News Today IRIDEX News Today Beyond Air News Today ReWalk Robotics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
